Bristol-Myers Squibb BuSpar
This article was originally published in Pharmaceutical Approvals Monthly
Marketing exclusivity for buspirone tablets extended through Nov. 22 on the basis of pediatric studies requested by FDA. The pediatric data was submitted in an sNDA that FDA found "approvable" Aug. 2
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.